ClinicalTrials.gg
CompletedNCT05972967Updated Oct 1, 2025

Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab

A Phase 2 interventional study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Omeros Corporation. Completed at 5 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Omeros Corporation · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2025.
  • Registered 3 months after the study started (first participant enrolled Mar 2023, registered Jul 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Hemoglobinuria, Paroxysmal with a site in Germany — 2 open to participants now, 7 under way, 4 of them phase 3. Hemoglobinuria, Paroxysmal · Germany.

Enrollment
20th of 21
12 · median 75
Started
2023
with 2 others
Phase 2
6 of 24
none open now
Registered
21st of 24
by date
Lead sponsor
2 of 24
Omeros Corporation

Among the 24 studies in Hemoglobinuria, Paroxysmal with a site in Germany, this one is the 20th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2023, is one of 6 in phase 2, and was the 21st registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

2 of the 24 studies in Hemoglobinuria, Paroxysmal with a site in Germany are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hemoglobinuria, Paroxysmal with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of OMS906 for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in patients who have a sub-optimal response to ravulizumab.

Read the detailed description

This is a Phase 2, proof of concept, open label study examining two doses of OMS906, 3 mg/kg and 5 mg/kg IV given to PNH patients at 8-week intervals, first in combination with the C5 inhibitor ravulizumab then as monotherapy. The primary objective is to assess overall safety and tolerability of repeat-dose IV OMS906 administration at 8-week intervals in patients with PNH.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • PNH
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of PNH by flow cytometry with PNH clone size of > 10% red blood cells (RBCs) and/or granulocytes.
  2. Male or female adults 18 years and older.
  3. Completed procedures.
  4. In relation to ravulizumab treatment prescribed in accordance with its marketing authorization and summary of product characteristics (SmPC):

    • Must have a sub-optimal response to ravulizumab, defined as a level \< 10.5 g/dL despite treatment measured at screening and confirmed at baseline (Day 1, predose). Ravulizumab treatment will have been maintained at a stable dose for at least 2 doses (4 months) prior to baseline.
  5. Female patients of must have a negative highly sensitive urine pregnancy test at screening and prior to each dose of OMS906.
  6. Females must use highly effective to prevent pregnancy during the clinical trial and for 20 weeks (140 days) following their last dose of study drug. If a female, must be sterile (either surgically or biologically)* or at least one year **, or have a monogamous partner who is surgically sterile, or have a same sex partner, or if in a heterosexual relationship, must agree to comply with the following contraception guidelines:

    • Practice abstinence (only considered an acceptable method of contraception when it is in line with the patients' usual and preferred lifestyle and the patient agrees to refrain from heterosexual intercourse during the entire period of risk associated with the study treatments, including during the clinical trial and for 20 weeks [140 days] following their last dose of study drug), or
    • Use at least 1 of the following medically acceptable methods of birth control:

      • Hormonal methods as follows:

    Combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal). Progestogen only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)

    • Intrauterine devices
    • Intrauterine hormone-releasing systems
    • Vasectomized partner * Defined as having had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; or have a congenital or acquired condition that prevents childbearing.

      • Defined as at least 12 months with no menses without an alternative medical cause) [can be confirmed with follicle stimulating hormone level (FSH) in the postmenopausal range (FSH levels ≥40 milli-International unit (mIU)/mL at Screening) if the patient is not using hormonal contraception or on hormonal replacement therapy]. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
  7. Males must use highly effective birth control with a female partner to prevent pregnancy during the clinical trial and for 20 weeks (140 days) following their last dose of study drug that include the following:

    • Practice abstinence (only considered an acceptable method of contraception when it is in line with the patients' usual and preferred lifestyle and the patient agrees to refrain from heterosexual intercourse during the entire period of risk associated with the study treatments, including during the clinical trial and for 20 weeks [140 days] following their last dose of study drug), or
    • Use (or have their partner use) acceptable, highly effective contraception (see Criterion #6) during heterosexual activity.

Exclusion criteria

Exclusion Criteria:

  1. History of major organ transplant or hematopoietic stem cell/marrow transplant.
  2. count \< 30,000/µL or \< 500 cells/µL at Screening.
  3. Anemia, as evidenced by \< 10.5 g/dL, attributable to any other medical condition apart from PNH.
  4. Elevation of liver function tests, defined as total > 2×, direct bilirubin > 1.5× upper limit of normal (ULN), and elevated transaminases, (ALT) or aspartate aminotransferase (AST), > 2×ULN unless due to PNH related hemolysis.
  5. History of any severe reactions to other monoclonal antibodies or included in the OMS906 preparation.
  6. Significant active bacterial or viral infection within the 2 weeks prior to Screening, including COVID-19 infection.
  7. Immunodeficiency or (including chronic use of immunosuppressive drugs, such as ciclosporin or tacrolimus).
  8. History of meningococcal disease and/or has not received vaccination for N. meningitidis.
  9. Pregnant, planning to become pregnant, or nursing female patients.
  10. Recent surgery requiring general anesthesia within the 2 weeks prior to Screening or expected to have surgery requiring general anesthesia during the Treatment Period.
  11. History of any significant medical, neurologic, or psychiatric disorder that in the opinion of the Investigator would make the patient unsuitable for participation in the study.
  12. Treatment with any medicinal product or investigational device within 30 days (or within 5× its half-life in days, whichever is the longer period) prior to Screening, or participation in another concurrent clinical trial involving a therapeutic intervention. Participation in observational and/or registry studies is permitted.
  13. Unable or unwilling to comply with the requirements of the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    3 mg/kg IV OMS906 with Ravulizumab IV

    Up to 6 doses of 3 mg/kg at 8-week intervals. All patients will receive 3 doses of OMS906 of 3 mg/kg Intravenous (IV) at 8-week intervals. Clinical responders at Week 24 will receive an additional 3 doses of OMS906 only at 8-week intervals at 5 mg/kg (monotherapy). Incomplete responders may receive an additional 3 doses of OMS906 with ravulizumab at 8-week intervals. Non responders will not receive additional OMS906.

    Biological: OMS906

  • Experimental
    5 mg/kg IV OMS906 with Ravulizumab IV

    Up to 6 doses of 5 mg/kg at 8-week intervals. All patients will receive 3 doses of OMS906 of 5 mg/kg Intravenous (IV) at 8-week intervals. Clinical responders at Week 24 will receive an additional 3 doses of OMS906 only at 8-week intervals (monotherapy). Incomplete responders may receive an additional 3 doses of OMS906 with ravulizumab at 8-week intervals. Non responders will not receive additional OMS906.

    Biological: OMS906

Interventions

  • BiologicalOMS906

    Biological: OMS906

    Also known as: zaltenibart

06

What researchers measure

Primary outcomes

  1. To assess the overall OMS906 administration at 8-week intervals in PNH patients.

    Number and % of participants with Treatment-emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0, including abnormalities in laboratory measures, ECGs and physical examinations

    Time frame: 56 weeks

Secondary outcomes

  1. Incidence of patients with hemoglobin increase ≥ 2.0 g/dL from baseline (Response criterion) baseline on adjunctive treatment and sustained during monotherapy.

    Number and % of participants with hemoglobin increase ≥ 2.0 g/dL from baseline on adjunctive treatment and sustained during monotherapy

    Time frame: 56 weeks

  2. Reticulocyte count

    Individual patient changes from baseline in absolute reticulocyte counts

    Time frame: 56 weeks

  3. Lactate dehydrogenase (LDH)

    Individual patient changes from baseline in LDH

    Time frame: 56 weeks

  4. Transfusion requirements

    Number of transfusions required during each treatment phase will be compared with the transfusion history prior to the study

    Time frame: 56 weeks

  5. Pharmacokinetics (PK) of multiple-dose administration of OMS906

    PK parameters including OMS906 maximum concentration (Cmax) and Area under the plasma concentration versus time curve (AUC)

    Time frame: 56 weeks

  6. Pharmacodynamics (PD) of multiple-dose administration of OMS906

    Mature Complement Factor D (CFD) concentration

    Time frame: 56 weeks

  7. OMS906 anti-drug antibodies (ADA)

    Number of patients with measurable ADA

    Time frame: 56 weeks

07

Study locations

5 sites
  • Omeros Investigational Site
    Aachen, Germany
  • Omeros Investigational Site
    Ulm, Germany
  • Omeros Investigational Site
    Thessaloniki, Greece
  • Omeros Investigational Site
    Lausanne, Switzerland
  • Omeros Investigational Site
    Leeds, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Oct 2024, 18 months.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 18 months is above that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Aug 2, 2023
StartActual
Mar 27, 2023
Primary completionActual
Oct 10, 2024
CompletionActual
Oct 10, 2024
Results delay requested
Sep 26, 2025
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05972967
Lead sponsor
Omeros Corporation
Responsible party
Sponsor
First posted
Aug 2, 2023
Start date
Mar 27, 2023
Primary completion
Oct 10, 2024
Completion
Oct 10, 2024
Last update
Oct 1, 2025

Study contacts

Edward Philpot, MD
study director · Omeros Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zaltenibart

Start the discussion